RxDoctor Payments Data

Neeraj Mehta, MD

Cardiovascular Disease · Alabaster, ALNPI 1003029869

Payments from drug & device makers

$4,633in general payments, 2019–2025

Across 79 payments — averaging $58.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$2K
  • Medtronic$831
  • Abbott$359
  • Novartis$256
  • Bard Peripheral Vascular, Inc.$141
  • Boehringer Ingelheim$125
  • plus $643 from 14 others

What the payments were for

  • Travel & lodging$71615%
  • Food & beverage$1,65336%
  • Education$140%
  • Other$2,25049%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,633 in reported general payments places this provider in the 55th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$448,267
Medicare patients
522
Services billed
4,696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban450$399,286
Repatha SureclickEvolocumab106$87,907
XareltoRivaroxaban78$78,009
BrilintaTicagrelor73$45,293
FarxigaDapagliflozin Propanediol40$29,436
Praluent PenAlirocumab25$13,859
EntrestoSacubitril/Valsartan16$12,562
Atorvastatin Calcium803$11,113
Ezetimibe268$8,887
Metoprolol Succinate487$6,766
Ranolazine ErRanolazine76$6,670
Rosuvastatin Calcium253$6,230
Nebivolol Hcl52$5,955
Amlodipine Besylate559$4,329
Losartan Potassium342$4,301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$66$399,286450 claims
Johnson & JohnsonXarelto$104$78,00978 claims
AstraZenecaBrilinta, Farxiga$14$74,728113 claims
NovartisEntresto$256$12,56216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Alabaster

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →